📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 17:33
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Laxmi Organic announces resignation of CPO and CTO effective October 31, 2026
Laxmi Organic Industries Limited announced that Dr. Keshav Ruthia (Chief Procurement Officer) and Mr. Salil Mukundan (Chief Technology Officer) have resigned to pursue external opportunities. Both executives will be relieved from their duties with effect from the close of business hours on October 31, 2026. As part of an ongoing organizational realignment, their responsibilities will be integrated within the existing leadership structure without like-for-like replacements.
Confidence: HIGH
What changedTwo key Senior Management Personnel (Chief Procurement Officer and Chief Technology Officer) have resigned and will leave the company on October 31, 2026.
Why it mattersCTO and CPO functions are critical to plant expansion projects and raw material sourcing; their internal absorption without direct replacement tests management bandwidth.
CPO Resignation Date: August 3, 2026CTO Resignation Date: August 18, 2026Effective Date of Cessation: October 31, 2026Direct replacements planned: None
📅 Short termOperational disruption is unlikely in the immediate term given the nearly 2.5-month planned transition window through October 31, 2026.
📈 Long termThe integration of technology and procurement roles into the existing leadership structure will need to sustain execution on the company's major specialty chemical and capacity ramp-ups.
⚠ Risk flags
- Execution and technical oversight risks during large project pipeline rollouts
- Procurement and vendor management transition risk
Key Highlights
Chief Procurement Officer Dr. Keshav Ruthia tendered his resignation vide letter dated August 3, 2026
Chief Technology Officer Mr. Salil Mukundan tendered his resignation vide email dated August 18, 2026
Both senior executives will be relieved from duties on October 31, 2026, allowing a transition window
Company will absorb responsibilities into the existing leadership structure without immediate like-for-like replacements
👀 What to Watch
Monitor the execution and commissioning timeline of upcoming expansion projects in H2 FY26 (such as Dahej and Lote facilities) for any operational or tech transition bottlenecks.
Laxmi Organic Announces Resignation of CPO and CTO Effective October 31, 2026
Laxmi Organic Industries Limited announced the resignation of two senior management executives: Dr. Keshav Ruthia (Chief Procurement Officer) and Mr. Salil Mukundan (Chief Technology Officer). Both executives will be relieved from their duties at the close of business on October 31, 2026. As part of an ongoing organizational realignment, the company is integrating these responsibilities into its existing leadership structure without immediate like-for-like senior replacements. The company has a TTM revenue base of ₹3,117 Cr and is actively ramping up specialty chemical operations.
Confidence: HIGH
What changedTwo key Senior Management Personnel (CPO and CTO) have resigned, with their duties being absorbed by existing leadership.
Why it mattersProcurement efficiency and technology leadership are critical for specialty chemical expansions and margin stability across a ₹3,117 Cr revenue operation.
CPO Resignation Tender Date: August 3, 2026CTO Resignation Tender Date: August 18, 2026Effective Date of Cessation: October 31, 2026TTM Revenue Context: ₹3,117 Cr
📅 Short termOperational continuity is supported by a nearly three-month handover period extending through October 31, 2026.
📈 Long termLimited, provided internal leadership successfully absorbs project pipeline evaluations and raw material procurement responsibilities.
⚠ Risk flags
- Execution and handover risks across planned chemical pipeline projects
- Simultaneous loss of two senior functional heads
Key Highlights
Dr. Keshav Ruthia tendered resignation as Chief Procurement Officer vide letter dated August 3, 2026.
Mr. Salil Mukundan tendered resignation as Chief Technology Officer vide email dated August 18, 2026.
Both senior executives will be relieved effective closing of business hours on October 31, 2026.
No direct like-for-like executive replacements planned; responsibilities being absorbed internally.
👀 What to Watch
Track the execution of key ongoing expansion projects at Dahej and Lote facilities during the management transition leading up to Q3 FY27.
40% YoY Revenue Growth in Q1 FY27; Dahej Phase 2 Ramp-up Targeted for Q4
Laxmi Organic reported a strong Q1 FY27 with revenue of ₹968.3 Cr, representing a 40% YoY and 32% sequential growth. The company is nearing the end of its major capex cycle, with the Dahej Phase 2 project expected to reach mechanical completion and stabilization in Q3 FY27. Management indicated that debt has peaked and repayments will commence in FY28 over a five-year period. While specialty margins have been under pressure due to a 10% revenue loss from a phased-out product, the company aims to return to 20-25% margins as new capacities ramp up.
Confidence: HIGH
What changedThe company is transitioning from a heavy investment/capex phase to an operational ramp-up phase, specifically at the Dahej site.
Why it mattersThe Dahej expansion is central to the company's strategy to become a top 3 global producer in diketene derivatives and to diversify into higher-margin fluorochemicals.
Q1 FY27 Revenue: ₹968.3 CrQ1 Revenue vs TTM Revenue: ~34.3%YoY Revenue Growth: 40%Incremental Depreciation: ₹7-7.5 Cr/quarterRevenue loss from phased-out product: 10%
📅 Short termThe strong Q1 performance and clarity on the capex timeline are likely to support positive sentiment in the coming weeks.
📈 Long termLong-term value depends on the successful ramp-up of the fluorochemicals business and achieving the targeted 20-25% margin profile in the specialty segment.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geopolitical volatility in West Asia affecting logistics and feedstock pricing
- Execution risk during the final stabilization phase of Dahej Phase 2
Key Highlights
Revenue for Q1 FY27 stood at ₹968.3 Cr, growing 40% year-on-year.
Dahej Phase 2 project mechanical completion and stabilization scheduled for Q3 FY27.
Incremental depreciation of ₹7 Cr to ₹7.5 Cr per quarter expected starting Q2 FY27 upon capitalization.
Specialty business previously impacted by the phase-out of a key product accounting for 10% of revenues.
Debt repayment for the peaked debt levels to begin in FY28 and continue for 5 years.
👀 What to Watch
Watch for the successful mechanical completion and customer qualification of the Dahej Phase 2 project in Q3 FY27, which is the key trigger for FY28 revenue growth.
LXCHEM Q1 FY27: PAT Surges 216% to ₹67.7 Cr; EBITDA Margins Expand to 11.8%
Laxmi Organic Industries (LXCHEM) reported a robust Q1 FY27 with consolidated revenue growing 40% YoY to ₹968.3 Cr, driven by volume and price growth across both Essentials and Specialties segments. Profitability saw a sharp recovery as PAT jumped 216% YoY to ₹67.7 Cr, while EBITDA margins expanded significantly by 740 bps to 11.8%. The company successfully commissioned its new Ethyl Acetate capacity at Lote and is on track for its Dahej Phase II expansion, with chemical charging expected in Q2 FY27. This performance marks a significant turnaround from the subdued margins seen in FY26.
Confidence: HIGH
What changedLXCHEM has moved from a period of margin compression (6.2% OPM in FY26) to a sharp recovery (11.8% in Q1 FY27) alongside the commissioning of new capacity at Lote.
Why it mattersThe strong margin expansion and volume growth indicate that the company is successfully navigating global chemical volatility and benefiting from its strategic shift toward higher-margin specialty chemicals.
Q1 FY27 Revenue: ₹968.3 CrQ1 FY27 PAT: ₹67.7 CrEBITDA Margin: 11.8%Revenue vs TTM Revenue: 34.3%YoY Revenue Growth: 40%
📅 Short termThe stock is likely to react positively to the significant earnings beat and the sharp expansion in operating margins compared to previous quarters.
📈 Long termStructural growth is supported by the doubling of Diketene capacity and the ramp-up of Fluorochemicals, aiming for a top 3 global position in specific chemistries.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geopolitical disturbances impacting feedstock prices
- Global overcapacity in specific chemical segments
- Execution risk in Dahej Phase II ramp-up
Key Highlights
Consolidated revenue increased 40% YoY to ₹968.3 Cr, representing ~34% of the total TTM revenue.
EBITDA grew 272% YoY to ₹114.3 Cr, with margins improving from 4.4% in Q1 FY26 to 11.8% in Q1 FY27.
Essentials segment revenue grew 50% YoY to ₹726.5 Cr, while Specialties grew 17% to ₹241.8 Cr.
Gross margins expanded by 660 bps YoY to 37.5% due to higher realizations and operating leverage.
Dahej Phase II expansion is progressing with chemical charging scheduled for Q2 FY27 and full ramp-up by Q4 FY27.
👀 What to Watch
Investors should monitor the execution timeline of the Dahej Phase II facility and the stabilization of the Fluorochemicals business, as these are critical for maintaining the current double-digit margin profile.
LXCHEM Q1 PAT Jumps 175% YoY to ₹63.3 Cr on 42% Revenue Growth
Laxmi Organic Industries (LXCHEM) reported a robust Q1 FY27 with revenue from operations reaching ₹957.73 Cr, a 42.5% increase YoY. Net profit surged 175.6% YoY to ₹63.30 Cr, nearly matching the entire TTM PAT of ₹79 Cr in a single quarter. The company benefited from improved operational performance and a shift to a lower tax regime of 25.17%. Profit Before Tax (PBT) showed a significant recovery, rising to ₹84.89 Cr from ₹17.75 Cr in the year-ago period.
Confidence: HIGH
What changedLXCHEM has delivered a significant earnings beat compared to its recent quarterly run rate, alongside a strategic shift to a lower corporate tax regime.
Why it mattersThe sharp recovery in profitability suggests that the company is overcoming previous pricing pressures in specialty chemicals and successfully ramping up higher-margin segments, which is critical for its high P/E valuation of 70.9.
Q1 Revenue: ₹957.73 CrQ1 PAT: ₹63.30 CrRevenue vs TTM Revenue: 33.9%PAT vs TTM PAT: 80.1%New Effective Tax Rate: 25.17%
📅 Short termThe stock is likely to react positively in the short term due to the substantial YoY and QoQ growth in both revenue and profitability.
📈 Long termIf this performance level is maintained, the company is on track for a significant re-rating as it moves toward its goal of becoming a top 3 global producer in specific chemistries by H2 FY26.
⚠ Risk flags
- Raw material price volatility
- Global pricing pressure in the Essentials (commodity) segment
- Execution risk for upcoming H2 FY26 capacity expansions
Key Highlights
Revenue from operations grew 42.5% YoY to ₹957.73 Cr from ₹671.91 Cr.
Net Profit (PAT) increased 175.6% YoY to ₹63.30 Cr, representing 80% of the total FY26 PAT.
Profit Before Tax (PBT) jumped 378% YoY to ₹84.89 Cr compared to ₹17.75 Cr in Q1 FY26.
Adopted a new tax regime under Section 115BAA with an effective rate of 25.17%.
Raw material costs stood at ₹617.54 Cr, accounting for approximately 64% of total revenue.
👀 What to Watch
Investors should monitor the sustainability of these improved margins and the progress of the diketene derivative and fluorochemicals capacity expansions scheduled for H2 FY26.
15% Final Dividend Announced; AGM Scheduled for August 05, 2026
Laxmi Organic Industries has issued a notice for its 37th Annual General Meeting (AGM) to be held on August 05, 2026. The company has recommended a final dividend of ₹0.30 per equity share (15% of face value) for FY26, with a record date of July 21, 2026. A significant agenda item includes a special resolution to ensure minimum remuneration for three Executive Directors for FY26-FY28, even in the event of inadequate profits. This comes as the company manages a TTM PAT of ₹79 Cr and prepares for capacity expansions in H2 FY26.
Confidence: HIGH
What changedThe company has formalized the schedule for its annual shareholder meeting and set the timeline for its FY26 final dividend payout.
Why it mattersThe dividend provides a modest cash return to shareholders, while the special resolution on executive pay ensures leadership stability despite the cyclicality and current margin pressures in the chemical sector.
Final Dividend: ₹0.30 per shareDividend Percentage: 15%Record Date: July 21, 2026AGM Date: August 05, 2026Cost Auditor Remuneration: ₹0.27 MillionDividend Yield (Approx): 0.18%
📅 Short termThe stock may see minor activity around the July 21 record date as it goes ex-dividend.
📈 Long termLimited structural impact from this routine filing; long-term value depends on the successful ramp-up of fluorochemicals and diketene capacity expected in H2 FY26.
⚠ Risk flags
- Executive remuneration may remain high even if company profitability remains under pressure.
Key Highlights
Final dividend of ₹0.30 per equity share (15% on ₹2 face value) recommended for FY26.
Record date for dividend entitlement set for July 21, 2026.
AGM to be conducted via video conferencing on August 05, 2026, at 11:00 AM.
Special resolution proposed for executive remuneration for FY26, FY27, and FY28 in case of profit inadequacy.
Ratification of ₹0.27 Million remuneration for Cost Auditors for the financial year ending March 31, 2027.
👀 What to Watch
Investors should note the record date of July 21, 2026, for dividend eligibility and monitor the voting results of the special resolution regarding executive pay during low-profit periods.
Laxmi Organic Corrects Q4 EPS to ₹0.77; Declares ₹0.30 Dividend & Appoints New CFO
Laxmi Organic Industries clarified a typographical error in its Q4 FY26 results, correcting the Consolidated EPS from a negative figure to ₹0.77. The Board has recommended a final dividend of ₹0.30 per share (15% of face value) for FY26, with the record date set for July 21, 2026. Furthermore, the company announced the appointment of Mr. Amit Jain as the new Chief Financial Officer, effective June 16, 2026. The annual financial results for FY26 were approved with an unmodified audit opinion.
Key Highlights
Corrected Q4 FY26 Consolidated Basic and Diluted EPS to ₹0.77 from incorrectly reported negative values.
Recommended a final dividend of ₹0.30 per equity share of face value ₹2 (15% payout).
Appointed Mr. Amit Jain as Chief Financial Officer effective June 16, 2026, replacing the interim CFO.
Fixed July 21, 2026, as the record date for dividend eligibility and August 5, 2026, for the AGM.
Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified opinion on FY26 financial results.
👀 What to Watch
Investors should update their records with the corrected EPS of ₹0.77 for Q4 FY26 to accurately assess valuation. Monitor the transition to the new CFO for any shifts in financial strategy or capital allocation.
Laxmi Organic Q4 FY26: Sequential Revenue Up 9% Despite 6% Annual Decline; New CFO Appointed
Laxmi Organic Industries reported a 9% sequential revenue growth in Q4 FY26, showing recovery across its Essentials and Specialties segments. However, full-year FY26 revenue declined by 6% compared to FY25 due to deflationary feedstock environments and margin pressures. The company is making progress on its expansion, with the Lote fluorination facility reaching 40-45% of peak revenue and Dahej Phase 2 expected to contribute to earnings in H2 FY27. Additionally, the company appointed Amit Jain as the new CFO to lead strategic growth.
Key Highlights
Q4 FY26 revenue grew 9% sequentially with margin improvements in both Essentials and Specialties businesses.
Full-year FY26 revenue saw a 6% YoY decline, attributed to global deflationary pressures and one-time effects.
The Lote fluorination facility achieved 40-45% of its peak revenue target during FY26.
Acetic acid prices showed extreme volatility, spiking from $350 to over $700 before moderating to $450-$470 levels.
Phase 2 of the Dahej project is scheduled for chemical charging in Q1 FY27, with revenue impact expected in H2 FY27.
👀 What to Watch
Investors should focus on the successful commissioning and revenue ramp-up of the Dahej Phase 2 project in H2 FY27 as a key growth catalyst. While sequential recovery is positive, the doubling of logistics costs and raw material volatility remain near-term headwinds to monitor.
Laxmi Organic Commissions Ethyl Acetate Plant at Lote Site; Starts Commercial Dispatches
Laxmi Organic Industries has successfully commissioned its new Ethyl Acetate plant at Manufacturing Site-III in Lote Parshuram, Maharashtra. The facility has officially commenced commercial dispatches, marking a key milestone in the company's growth strategy. This expansion is designed to strengthen the company's operational capabilities and market presence in the specialty chemicals space. Investors should watch for the revenue contribution from this new capacity in the subsequent financial quarters.
Key Highlights
Successfully commissioned Ethyl Acetate Plant at Manufacturing Site-III in Lote Parshuram, Maharashtra.
Commencement of commercial dispatches marks the transition from project phase to operational phase.
Expansion project is a key part of the company's strategic growth and capacity enhancement initiatives.
Expected to bolster market share in the Acetyl Intermediates segment and improve operational scale.
👀 What to Watch
Investors should maintain a positive outlook as the new capacity begins contributing to the top line. Track utilization rates and margin impact in the next few earnings cycles.
Laxmi Organic Corrects Q4 EPS to ₹0.77, Declares ₹0.30 Dividend & Appoints New CFO
Laxmi Organic Industries clarified a typographical error in its Q4 FY26 results, correcting the reported EPS from a negative ₹(0.77) to a positive ₹0.77. The Board has recommended a final dividend of ₹0.30 per share (15% of face value) for the financial year 2025-26, with the record date set for July 21, 2026. Furthermore, the company has appointed Mr. Amit Jain, a professional with over 30 years of experience, as the permanent Chief Financial Officer effective June 16, 2026. The statutory auditors have provided an unmodified opinion on the financial results, confirming the reliability of the corrected figures.
Key Highlights
Corrected Q4 FY26 Basic and Diluted EPS to ₹0.77 from the incorrectly reported negative figures
Recommended a final dividend of ₹0.30 per equity share (15% of face value) for FY 2025-26
Appointed Mr. Amit Jain as Chief Financial Officer effective June 16, 2026
Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified opinion on FY26 results
Set July 21, 2026, as the record date for dividend eligibility and August 5, 2026, for the AGM
👀 What to Watch
Investors should take note of the EPS correction which confirms quarterly profitability and view the appointment of a seasoned CFO as a positive step for financial leadership. The dividend yield is modest, but the record date of July 21 is the key timeline for eligible shareholders.
Laxmi Organic Reports FY26 Revenue of ₹2,847 Cr; New Products Contribute 20% to Topline
Laxmi Organic Industries reported a consolidated revenue of ₹2,847 crore for FY26, reflecting a slight decline from ₹2,986 crore in FY25 due to a subdued global chemical environment. The company is strategically pivoting toward specialty chemicals, with its Dahej site planned to host a 60% specialty product mix. A significant milestone includes the inauguration of a new $8 million Innovation Centre in Navi Mumbai to drive R&D. Despite market headwinds, the company maintains its leadership as the #1 Diketene derivative manufacturer in India and has achieved over 20% revenue contribution from products launched in the last five years.
Key Highlights
FY26 total revenue stood at ₹2,847 crore compared to ₹2,986 crore in the previous fiscal year.
New products launched within the last 5 years now account for over 20% of total revenue.
Invested $8 million in a state-of-the-art 30,000 sq. ft. Innovation Centre in Navi Mumbai.
Maintains #1 market position in India for both Essentials and Diketene-based Specialties.
Dahej site (Site 4) expansion is geared for growth with a target product mix of 60% Specialties.
👀 What to Watch
Investors should monitor the ramp-up of the Dahej facility and the margin profile of the Specialties segment, which is expected to drive future value. While revenue growth is currently flat, the company's focus on R&D and high-value fluorospecialties provides a long-term competitive edge.
Laxmi Organic Industries Sets July 21, 2026, as Record Date for Final Dividend
Laxmi Organic Industries Limited (LXCHEM) has fixed July 21, 2026, as the record date to determine shareholder eligibility for the final dividend of FY 2025-26. The dividend payment is contingent upon approval from shareholders at the company's 37th Annual General Meeting (AGM). This AGM is scheduled to be held on August 5, 2026. Investors must hold the stock before the ex-dividend date to qualify for the payout.
Key Highlights
Record date for final dividend eligibility is set for July 21, 2026
Dividend pertains to the financial year ending March 31, 2026
37th Annual General Meeting (AGM) to be conducted on August 5, 2026
Final dividend distribution is subject to shareholder approval at the AGM
👀 What to Watch
Investors seeking to receive the dividend should ensure they own the shares before the ex-dividend date. Monitor the AGM outcome for the specific dividend per share amount and payment timelines.
Laxmi Organic FY26 PAT Drops 30% to ₹794M; Declares ₹0.30 Dividend & Appoints New CFO
Laxmi Organic reported a weak set of annual results for FY26, with consolidated net profit declining 30% YoY to ₹793.62 million from ₹1,135.04 million in FY25. Annual revenue also saw a contraction of 4.6%, falling to ₹28,466.67 million. Despite the annual decline, Q4 revenue showed a marginal recovery of 3.6% YoY, reaching ₹7,353.10 million. The company has recommended a final dividend of ₹0.30 per share and appointed Amit Jain as the new CFO to strengthen its leadership team.
Key Highlights
Consolidated Net Profit for FY26 fell 30.1% YoY to ₹793.62 million compared to ₹1,135.04 million in the previous year.
Annual Consolidated Revenue from Operations decreased 4.6% YoY to ₹28,466.67 million.
Recommended a final dividend of ₹0.30 per equity share (15% of face value) for FY25-26.
Appointed Mr. Amit Jain as Chief Financial Officer effective June 16, 2026, to succeed the interim CFO.
Q4 FY26 consolidated revenue stood at ₹7,353.10 million, a slight 3.6% increase over the same quarter last year.
👀 What to Watch
Investors should exercise caution as the significant drop in annual profitability indicates margin pressure within the specialty chemicals segment. Monitor the new CFO's impact on operational efficiencies and wait for signs of sustained margin recovery in upcoming quarters.
Laxmi Organic CFO Mahadeo Karnik Resigns; Interim CFO Appointed with Successor Joining June 15
Laxmi Organic Industries has announced that its Chief Financial Officer, Mr. Mahadeo Karnik, will resign effective April 13, 2026. To manage the transition, the company has appointed Executive Director Mr. Harshvardhan Goenka as the Interim CFO starting April 14, 2026. Notably, the company has already identified a permanent successor who is expected to join by June 15, 2026. This clear timeline for succession helps mitigate concerns regarding leadership gaps in the finance department.
Key Highlights
CFO Mahadeo Karnik to step down from his role effective April 13, 2026.
Executive Director Harshvardhan Goenka, with 13+ years of experience, to serve as Interim CFO from April 14, 2026.
A permanent successor has been identified and is tentatively expected to join the firm on June 15, 2026.
The transition period under interim leadership is expected to last approximately 60 days.
👀 What to Watch
Investors should view this as a routine leadership transition given the proactive identification of a successor. Monitor the formal joining of the new CFO in June to ensure continuity in financial strategy.
Laxmi Organic Faces ₹40.7 Crore Potential Impact as MSEDCL Appeals MERC Order
Maharashtra State Electricity Distribution Company Limited (MSEDCL) has filed an appeal before the Appellate Tribunal for Electricity (APTEL) challenging a previous order that was ruled in favor of Laxmi Organic Industries. The appeal includes an application for a 116-day delay condonation, which is currently pending admission by the tribunal. If the appeal is admitted and a stay is granted, the company faces a maximum potential financial exposure of ₹407.27 million plus interest. The company believes the appeal is unsustainable as the matter was already technically adjudicated by the Maharashtra Electricity Regulatory Commission (MERC).
Key Highlights
MSEDCL is challenging the MERC Final Order dated September 17, 2025, which was originally in favor of the company.
Maximum potential financial impact is quantified at ₹407.27 million plus applicable interest.
The appeal is currently at the pre-admission stage with a 116-day delay condonation application pending.
The company maintains that the appeal is not sustainable based on previous technical examinations by MERC.
👀 What to Watch
Investors should monitor whether APTEL admits the appeal or rejects the condonation of delay, as the latter would resolve the liability risk. The ₹40.7 crore figure is significant enough to impact short-term sentiment if the tribunal grants a stay.
CRISIL Downgrades Laxmi Organic's Long-Term Rating to 'AA-/Negative' on Margin Pressure
CRISIL has downgraded Laxmi Organic Industries' long-term rating to 'AA-/Negative' from 'AA/Negative' while maintaining a Negative outlook. The downgrade is driven by a steeper-than-expected decline in revenue and profitability, with 9M FY26 operating margins falling to 4.4% from 9.5% YoY. While the company maintains a healthy capital structure with gearing at 0.17x, the return on capital employed (RoCE) is expected to drop to low single digits this fiscal due to high capex and lower earnings.
Key Highlights
Long-term bank facilities downgraded to 'CRISIL AA-/Negative'; short-term rating reaffirmed at 'CRISIL A1+'
9M FY26 revenue declined 9% YoY to ₹2,071 crore, with specialty chemical sales dropping 22%
Operating margins compressed to 4.4% from 9.5% due to pricing pressure and phase-out of high-margin products
Interest coverage ratio deteriorated significantly to 6.00x from 18.68x in the previous year
Company is executing a major ₹700 crore capex in FY26, with ₹475 crore already deployed by December 2025
👀 What to Watch
Investors should exercise caution as the negative outlook reflects sustained pressure on margins and slow recovery in return ratios. Monitor the successful ramp-up of the new Dahej facility, which is critical for restoring profitability to the projected 7-9% range.
Laxmi Organic Q3 PAT Drops 28.7% YoY to ₹198 Million; Revenue Down 8%
Laxmi Organic Industries reported a weak Q3 FY26 with revenue from operations declining 8% YoY to ₹7,068.72 million. Profit After Tax (PAT) fell 28.7% YoY to ₹198.31 million, despite being supported by significant one-time items and accounting changes. The company changed its depreciation method to Straight Line (SLM), without which it would have reported a loss before tax of ₹53.16 million for the quarter. Additionally, the bottom line was aided by a ₹407.27 million reversal of electricity-related liabilities and a ₹97.18 million deferred tax credit from adopting a new tax regime.
Key Highlights
Revenue from operations decreased to ₹7,068.72 million in Q3 FY26 from ₹7,678.72 million in Q3 FY25.
Profit After Tax (PAT) declined to ₹198.31 million compared to ₹278.15 million in the same quarter last year.
Change in depreciation method from WDV to SLM prevented a reported pre-tax loss of ₹53.16 million for the quarter.
One-time reversal of ₹407.27 million in electricity charges (MSEDCL) recorded under other operating income.
Adoption of lower tax rate (25.17%) resulted in a one-time deferred tax reversal of ₹97.18 million.
👀 What to Watch
Investors should note that the reported profit is heavily reliant on accounting adjustments and one-time reversals rather than operational strength. Caution is advised as core chemical business margins appear under pressure.
LXCHEM Q3 FY26: Adjusted EBITDA at ₹14 Cr; Dahej Phase 2 Completion Targeted for Q4
Laxmi Organic reported a 9% YoY revenue decline and a 33% drop in EBITDA to ₹50 crores for Q3 FY26, though this included a ₹40.7 crore one-time litigation gain. Excluding one-timers, adjusted EBITDA stood at a weak ₹14 crores as the Specialties segment saw a 30% revenue drop due to price moderation and product phase-outs. The Essentials segment faced subdued spreads, though ethyl acetate margins are recovering toward $130 as acetic acid prices rebound from lows. Management expects the major Dahej Phase 2 expansion to be completed by the end of Q4 FY26, which is critical for future volume growth.
Key Highlights
Reported EBITDA of ₹50 crores includes a ₹40.7 crore one-time gain from a favorable Supreme Court order on wheeling charges.
Specialties revenue declined 30% YoY, impacted by a 10% hit from an agrochemical intermediate phase-out and 12% from price moderation.
Essentials segment revenue fell 6% YoY despite stable volumes, reflecting a 20% plus drop in acetic acid feedstock prices over two years.
Ethyl acetate spreads improved from $90-$100 to approximately $130 as acetic acid prices rebounded to $360-$380 in December.
Phase 2 of the Dahej facility, the company's largest capex project, is on track for completion by the end of Q4 FY26.
👀 What to Watch
Investors should monitor the ramp-up of the Dahej Phase 2 facility and the sustainability of the recovery in ethyl acetate spreads. While current operational margins are under significant pressure, the completion of major capex and stabilizing feedstock prices could signal an operational turnaround in FY27.
Laxmi Organic Q3 FY26 Update: Focus on Specialties Growth and $8M R&D Investment
Laxmi Organic Industries (LXCHEM) presented its Q3 and 9M FY26 performance, highlighting a revenue base of approximately $300 million and a strategic shift toward a customer-centric business model. The company is leveraging its new $8 million Innovation Centre in Navi Mumbai to drive high-margin growth in its Specialties segment, including fluorospecialties. With a massive 116-acre brownfield site in Dahej currently less than 20% occupied, the company has significant long-term capacity for expansion. The Essentials business maintains its market leadership in India, supported by a 25% green power mix.
Key Highlights
Annual revenue stands at approximately $300 million with a portfolio of 50+ products serving 650+ customers.
Invested $8 million in a new 30,000 sq. ft. Innovation Centre to enhance R&D and process engineering capabilities.
Significant expansion potential at the Dahej site (116 acres) with current land occupancy below 20%.
Successfully completed ISCC Plus certification for the Dahej site in November 2025, boosting sustainability credentials.
Specialties segment now includes 30+ Diketene derivatives and is scaling up fluorination and mercaptan chemistries.
👀 What to Watch
Investors should track the margin improvement resulting from the shift toward the Specialties segment and the utilization of the Dahej land parcel. The company's transition to a customer-centric model and R&D focus makes it a key player to watch in the specialty chemical recovery cycle.
Laxmi Organic Approves Q3 FY26 Results and Re-appoints Dr. Rajiv Banavali as Director
Laxmi Organic Industries has approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board also approved the re-appointment of Dr. Rajiv Banavali as an Independent Director for a second term of two years, starting May 18, 2026. Dr. Banavali brings over 38 years of global experience in the chemicals sector, including leadership roles at WestRock and Honeywell. The re-appointment is subject to shareholder approval through a postal ballot process.
Key Highlights
Approved Unaudited Consolidated and Standalone Financial Results for Q3 and Nine Months ended Dec 31, 2025.
Re-appointed Dr. Rajiv Banavali as Independent Director for a second term from May 18, 2026, to May 17, 2028.
Dr. Banavali holds a Ph.D. in chemistry and has 38+ years of experience in material sciences and innovation.
The Board meeting was conducted over a three-hour duration, concluding at 20:00 hours IST.
Shareholder approval for the director's re-appointment will be sought via a postal ballot notice.
👀 What to Watch
Investors should closely examine the detailed financial tables in Annexures A and B on the stock exchange websites to evaluate the company's margin performance and revenue growth. The retention of experienced technical leadership on the board is a positive sign for the company's long-term R&D initiatives.
